Celastrol suppresses breast cancer MCF-7 cell viability via the AMP-activated protein kinase (AMPK)-induced p53-polo like kinase 2 (PLK-2) pathway

Cellular Signalling

Volumn 25, Issue 4, 2013, Pages 805-813

  Kim, Ji Hae ^a   Lee, Jung Ok ^a   Lee, Soo Kyung ^a   Kim, Nami ^a   You, Ga Young ^a   Moon, Ji Wook ^a   Sha, Jie ^a   Kim, Su Jin ^a   Park, Sun Hwa ^a   Kim, Hyeon Soo ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

AMPK; Breast tumor; Celastrol; P53; PKCzeta; PLK 2

Indexed keywords

CELASTROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; POLO LIKE KINASE 2; PROTEIN KINASE C ZETA; PROTEIN P53; REACTIVE OXYGEN METABOLITE;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CELL VIABILITY; CONTROLLED STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

EID: 84873313731     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2012.12.005     Document Type: Article

References (29)

1. Li H., Zhang Y.Y., Huang X.Y., Sun Y.N., Jia Y.F., Li D. European Journal of Pharmacology 2005, 512:231-237.
2. Xu X., Wu Z., Xu C., Ren Y., Ge Y. Annals of the Rheumatic Diseases 2003, 62:377-378.
3. Pinna G.F., Fiorucci M., Reimund J.M., Taquet N., Arondel Y., Muller C.D. Biochemical and Biophysical Research Communications 2004, 322:778-786.
4. Cleren C., Calingasan N.Y., Chen J., Beal M.F. Journal of Neurochemistry 2005, 94:995-1004.
5. Yang H., Chen D., Cui Q.C., Yuan X., Dou Q.P. Cancer Research 2006, 66:4758-4765.
6. Sethi G., Ahn K.S., Pandey M.K., Aggarwal B.B. Blood 2007, 109:2727-2735.
7. Abbas S., Bhoumik A., Dahl R., Vasile S., Krajewski S., Cosford N.D., Ronai Z.A. Clinical Cancer Research 2007, 13:6769-6778.
8. Jung H.W., Chung Y.S., Kim Y.S., Park Y.K. Experimental & Molecular Medicine 2007, 39:715-721.
9. Huang Y., Zhou Y., Fan Y., Zhou D. Cancer Letters 2008, 264:101-106.
10. Zhang T., Hamza A., Cao X., Wang B., Yu S., Zhan C.G., Sun D. Molecular Cancer Therapeutics 2008, 7:162-170.
11. Kim Y., Kim K., Lee H., Han S., Lee Y.S., Choe J., Kim Y.M., Hahn J.H., Ro J.Y., Jeoung D. European Journal of Pharmacology 2009, 612:131-142.
12. Hardie D.G., Carling D., Carlson M. Annual Review of Biochemistry 1998, 67:821-855.
13. Hardie D.G. Endocrinology 2003, 144:5179-5183.
14. Hardie D.G., Sakamoto K. Physiology (Bethesda, Md.) 2006, 21:48-60.
15. Meisse D., Van de Casteele M., Beauloye C., Hainault I., Kefas B.A., Rider M.H., Foufelle F., Hue L. FEBS Letters 2002, 526:38-42.
16. Garcia-Gil M., Pesi R., Perna S., Allegrini S., Giannecchini M., Camici M., Tozzi M.G. Neuroscience 2003, 117:811-820.
17. Kefas B.A., Cai Y., Kerckhofs K., Ling Z., Martens G., Heimberg H., Pipeleers D., Van de Casteele M. Biochemical Pharmacology 2004, 68:409-416.
18. Saitoh M., Nagai K., Nakagawa K., Yamamura T., Yamamoto S., Nishizaki T. Biochemical Pharmacology 2004, 67:2005-2011.
19. Levine A.J. Cell 1997, 88:323-331.
20. Vogelstein B., Lane D., Levine A.J. Nature 2000, 408:307-310.
21. Gottlieb E., Vousden K.H. Cold Spring Harbor Perspectives in Biology 2010, 2:a001040.
22. Shackelford D.B., Shaw R.J. Nature Reviews. Cancer 2009, 9:563-575.
23. Gusarova G.A., Dada L.A., Kelly A.M., Brodie C., Witters L.A., Chandel N.S., Sznajder J.I. Molecular and Cellular Biology 2009, 29:3455-3464.
24. Gogna R., Madan E., Kuppusamy P., Pati U. Antioxidants & Redox Signaling 2012, 16:400-412.
25. Burns T.F., Fei P., Scata K.A., Dicker D.T., El-Deiry W.S. Molecular and Cellular Biology 2003, 23:5556-5571.
26. Lee J.H., Choi K.J., Seo W.D., Jang S.Y., Kim M., Lee B.W., Kim J.Y., Kang S., Park K.H., Lee Y.S., Bae S. International Journal of Molecular Medicine 2011, 27:441-446.
27. Habraken Y., Piette J. Biochemical Pharmacology 2006, 72:1132-1141.
28. Chiosis G., Neckers L. ACS Chemical Biology 2006, 1:279-284.
29. Hieronymus H., Lamb J., Ross K.N., Peng X.P., Clement C., Rodina A., Nieto M., Du J., Stegmaier K., Raj S.M., Maloney K.N., Clardy J., Hahn W.C., Chiosis G., Golub T.R. Cancer Cell 2006, 10:321-330.